A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2017
At a glance
- Drugs ABBV 838 (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 13 Apr 2017 Planned End Date changed from 1 Aug 2020 to 1 Jan 2021.
- 15 Feb 2017 Planned End Date changed from 1 Jan 2021 to 1 Aug 2020.
- 15 Feb 2017 Status changed from not yet recruiting to recruiting.